LifeArc identifies rare diseases as latest target

The UK-based non-profit medical research organization and charity LifeArc has announced a program to invest more than £100 million ($127 million) by 2030 to deliver new breakthroughs in rare diseases.

Its Rare Disease Translational Challenge will bring together researchers in rare disease with LifeArc’s expertise in translational science, bridging the gap between academic research and getting new developments to patients faster by providing funding, research and expert knowledge.

LifeArc has described the program as a ‘great leap forward in accelerating promising early-stage research in diagnostics, treatments and the re-purposing of drugs and getting them into clinical trials faster’.